Regional Difference in Seroprevalence of SARS-CoV-2 in Tokyo: Results from the community point-of-care antibody testing
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The serosurvey is an alternative way to know the magnitude of the population infected by coronavirus disease 2019 (COVID-19) since the expansion of capacity of the polymerase chain reaction (PCR) to detect the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was delayed. We herein report seroprevalence of COVID-19 accessed in the two community clinics in Tokyo. The point-of-care immunodiagnostic test was implemented to detect the SARS-CoV-2 specific IgG antibody in the peripheral capillary blood. The overall positive percentage of SARS-CoV-2 IgG antibody is 3.83% (95% confidence interval: 2.76-5.16) for the entire cohort ( n =1,071). The central Tokyo of 23 special wards exhibited a significantly higher prevalence compared to the other area of Tokyo ( p =0.02, 4.68% [95%CI: 3.08-6.79] versus 1.83 [0.68-3.95] in central and suburban Tokyo, respectively). The seroprevalence of the cohort surveyed in this study is low for herd immunity, which suggests the need for robust disease control and prevention. A community-based approach, rather than state or prefectural levels, is of importance to figure out profiles of the SARS-COV-2 outbreak.
Article activity feed
-
SciScore for 10.1101/2020.06.03.20121020: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The Institutional Review Board of Navitas Clinic approved the present study (Approval Number: NC2020-01).
Consent: Asymptomatic subjects have been recruited by web posting of our clinic, and written consent was obtained from all participants prior to the test.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources The SARS-CoV-2 specific IgG antibody in the peripheral capillary blood was detected by the point-of-care immunodiagnostic test (SARS-CoV-2 Antibody Testing Kit IgG RF-NC002, Kurabo Industries Ltd, Osaka, Japan) in the two community clinics … SciScore for 10.1101/2020.06.03.20121020: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The Institutional Review Board of Navitas Clinic approved the present study (Approval Number: NC2020-01).
Consent: Asymptomatic subjects have been recruited by web posting of our clinic, and written consent was obtained from all participants prior to the test.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources The SARS-CoV-2 specific IgG antibody in the peripheral capillary blood was detected by the point-of-care immunodiagnostic test (SARS-CoV-2 Antibody Testing Kit IgG RF-NC002, Kurabo Industries Ltd, Osaka, Japan) in the two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa). SARS-CoV-2 specific IgGsuggested: NoneSoftware and Algorithms Sentences Resources The descriptive and Fisher’s exact test was performed with IBM SPSS Statistics 26 (IBM Corp., Armonk, NY) SPSSsuggested: (SPSS, RRID:SCR_002865)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitation includes the selection bias and accuracy of the test kit. Concerns about the risk of COVID-19 infection such as past fever, illness of cohabitants or co-workers and working environment were common reasons for the participation of this study, which can cause elevation of seroprevalence. Less sensitivity of test kit develops the underestimation of the prevalence. Further serosurvey, along with the fine characterization of population, is warranted for the measurement of a future outbreak.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
SciScore for 10.1101/2020.06.03.20121020: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Methods The Institutional Review Board of Navitas Clinic approved the present study (Approval Number: NC2020-01). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources The overall positive percentage of SARS-CoV-2 IgG antibody is 3.83% (95% confidence interval: 2.76-5.16) for entire cohort (n =1,071). SARS-CoV-2 IgGsuggested: NoneThe SARS-CoV-2 specific IgG antibody in the peripheral capillary blood was detec by the point-of-care immunodiagnostic test (SARS-CoV-2 Antibody Testing Kit … SciScore for 10.1101/2020.06.03.20121020: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Methods The Institutional Review Board of Navitas Clinic approved the present study (Approval Number: NC2020-01). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources The overall positive percentage of SARS-CoV-2 IgG antibody is 3.83% (95% confidence interval: 2.76-5.16) for entire cohort (n =1,071). SARS-CoV-2 IgGsuggested: NoneThe SARS-CoV-2 specific IgG antibody in the peripheral capillary blood was detec by the point-of-care immunodiagnostic test (SARS-CoV-2 Antibody Testing Kit IgG RF-NC Kurabo Industries Ltd, Osaka, Japan) in the two community clinics located in the major railw stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa). SARS-CoV-2 specific IgGsuggested: NoneResults from OddPub: We did not find a statement about open data. We also did not find a statement about open code. Researchers are encouraged to share open data when possible (see Nature blog).
About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.
-
-